Cyanopyridine derivatives as liver X receptor beta agonists, compositions, and their use

US10239849B2 · kind B2 · utility

Assignee

• Merck Sharp & Dohme LLC · US

Inventors

• Michael T. Rudd · Collegeville, US
• Edward J. Brnardic · Lansdale, US
• Yuntae Kim · Seoul, KR
• Robert S. Meissner · Schwenksville, US
• Vanessa L. Rada · Hatfield, US
• Shawn J. Stachel · Perkasie, US
• Celina V. Zerbinatti · Hamburg, DE

Key dates

• Filing date: Nov 7, 2016
• Grant date: Mar 26, 2019
• Expiry date: Nov 7, 2036

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D515/04
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

In its many embodiments, the present invention provides substituted cyanopyridine containing compounds of the Formula (I): and acceptable salts thereof, wherein R1, R2, R3, R4, R5, X, Y, Q, and the moiety are as defined herein. The novel compounds of the invention, and pharmaceutically acceptable compositions comprising a compound thereof, are useful as Liver X-β receptor (LXRβ) agonists, and may be useful for treating or preventing pathologies related thereto. Such pathologies include, but are not limited to, inflammatory diseases and diseases characterized by defects in cholesterol and lipid metabolism, such as Alzheimer's disease.